ArticleFrontiers in oncology2022
Trends in Oropharyngeal Cancer Incidence Among Adult Men and Women in the United States From 2001 to 2018.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Oropharyngeal cancer risk groups in the United States: a meta-analysis and SEER analysis.BMC cancer · 2025Pooled it
- Article
- Closing the Gap: HPV Vaccination and Head and Neck Cancer Prevention.Current oncology reports · 2026Review
- High-Risk HPV in Men: A Hidden Threat to Public Health?Reviews in medical virology · 2026Review
- Knowledge and awareness regarding human papillomavirus and its association with oropharyngeal cancer among the general population in Makkah, Saudi Arabia: a cross-sectional study.Frontiers in oncology · 2026Article
- HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma.Frontiers in immunology · 2026Review
- Oropharyngeal cancer mortality in the United States, 1999-2023: a surveillance analysis using CDC WONDER.Frontiers in oncology · 2026Article
- Article
- Persistence and clearance of oral human papillomavirus among a multi-national cohort of men.Nature communications · 2025Article
- Circulating Tumor Tissue-Modified-Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Article
- Association Between Human Papillomavirus and Thymic Cancer: A Population-Based Cohort Study.Cancer management and research · 2025Article
- Multinational epidemiological analysis of oral human papillomavirus incidence in 3,137 men.Nature microbiology · 2024Observational
- Correlates of human papillomavirus vaccination intent for oropharyngeal cancer prevention among gay and bisexual men living in the United States.Journal of the American Dental Association (1939) · 2024Article
- Prevalence of Human Papillomavirus Infection and Cervical Abnormalities among Women Attending a Tertiary Care Center in Saudi Arabia over 2 Years.Tropical medicine and infectious disease · 2023Article
- Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).Oncology letters · 2023Review
- Incidence of human papillomavirus-related cancers among males and females aged 15-34 years in the United States.JNCI cancer spectrum · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Background: The human papillomavirus (HPV) vaccine was approved in 2006 and has been shown to decrease vaccine-related HPV types in the oropharynx. Its impact on the incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has not been examined. We investigated the impact of HPV vaccination on the incidence of HPV-related OPSCC in the US among male and female adults from different age groups. Methods: The US Cancer Statistics 2001-2018 database and the National Cancer Institute (NCI)'s Surveillance Epidemiology and End Results (SEER) program were used in this study. OPSCC incidence was age-adjusted to the US standard population in 2000. Cause-specific 5-year survival probability was calculated using 60 monthly intervals in SEER*Stat software. Results: Incidence of HPV-related OPSCC was much higher in males than in females. Age-adjusted annual incidence of OPSCC was significantly lower in 2014-2018 than in 2002-2006 among males 20-44 years old (11.4 vs 12.8 per 1,000,000, rate ratio 0.89, 95% confidence interval 0.84-0.93) and among females 20-44 years old (3.0 vs 3.6 per 1,000,000, rate ratio 0.86, 95% confidence interval 0.78-0.95), but increased in both 45-64 year old and 65+ year old males and females. Joinpoint regression revealed a significant joint in the HPV-OPSCC incidence trend for 20-44-year-old males in 2008 at which time the incidence began to decrease. Except for 20-44 year old females (74.8% in 2002-2006 vs. 75.7% in 2009-2013, p=0.84), cancer-specific 5-year survivals significantly improved for males and females of all age groups. Conclusions: HPV-related OPSCC was much more common in males. Incidence of HPV-related OPSCC declined among young adults during the vaccination era compared with pre-vaccination era. Cancer-specific 5-year survival was significantly improved in young males but not in young females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.